<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
-------------------------
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
-------------------------
DATE OF REPORT: November 23, 1999
(Date of earliest event reported)
PHOTOGEN TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
NEVADA 0-23553 36-4010347
(State or other jurisdiction (Commission File Number) (I.R.S. Employer
of incorporation or Identification No.)
organization)
7327 OAK RIDGE HIGHWAY, SUITE B
KNOXVILLE, TENNESSEE 37931
(Address of principal executive offices) (Zip Code)
(423) 769-4011
(Registrant's telephone number including area code)
<PAGE>
ITEM 5. OTHER EVENTS.
Photogen Technologies, Inc. (the "Company") issued a press release
announcing that the Company's common stock has been approved for listing on
the NASDAQ small cap market. The Press Release, dated November 23, 1999, is
attached as Exhibit 99 hereto.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(c) The following exhibit is filed with this report:
99 Press release of the Company, dated November 23, 1999, announcing
that the Company's common stock has been approved for listing on
the NASDAQ small cap market.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Photogen Technologies, Inc.
By: /s/ John Smolik
-----------------------------
John Smolik, President
Date: November 23, 1999
<PAGE>
EXHIBIT INDEX
<TABLE>
<CAPTION>
Exhibit Description
No.
<S> <C>
99 Press release of the Company, dated November 23, 1999,
announcing that the Company's common stock has been approved
for listing on the NASDAQ small cap market.
</TABLE>
<PAGE>
Exhibit 99
FOR IMMEDIATE RELEASE
PHOTOGEN TECHNOLOGIES' COMMON STOCK APPROVED FOR
LISTING ON NASDAQ SMALL CAP MARKET
KNOXVILLE, TENN., NOV. 23, 1999 -- Photogen Technologies, Inc. (OTC BB:
PHGN), a developmental stage company focused on non-invasive diagnostics and
therapies, today announced that its application to list its common stock on
the NASDAQ small cap market has been approved.
Trading of Photogen's common stock on the small cap market will commence
Monday, Nov. 29. The Company's stock symbol will be listed as NASDAQ: PHGN.
John Smolik, Photogen's president and CEO, stated, "Our approval by NASDAQ
represents a significant step in our corporate strategy to bring liquidity
and the benefits of NASDAQ listing to our holders of common stock."
ABOUT PHOTOGEN
Photogen Technologies, Inc. is a development-stage company focused on
creating therapeutic and diagnostic products based on its proprietary
multi-photon and other related technologies. The company has discovered new
methods for using energy from lasers, x-rays or other sources to activate
photoactive agents within tissue sufficient to produce a range of beneficial
therapeutic and diagnostic outcomes. These technologies involve methods,
materials and devices that may be used to produce light or other energy and
photoactive agents and to destroy diseased cells, remove tissue or identify
and diagnose disease. Photogen has U.S. patents and additional pending
applications in the U.S. and worldwide for certain of its proprietary
technology. The company has no products or operating revenue at this time.
SAFE HARBOR STATEMENT
Statements in this release that are not strictly historical are
"forward-looking" statements that are made pursuant to the safe harbor
provision of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements involve known and unknown risks, which may cause
the company's actual results in the future to differ materially from expected
results. These risks and uncertainties include: the ability of the company to
develop a product and obtain regulatory approval for its use; the ability of
the company to successfully market and sell any products and
<PAGE>
equipment; the company's ability to manufacture products in sufficient
quantities; the company's ability to maintain intellectual property
protection for its proprietary products, to defend its existing intellectual
property rights from challenges by third parties, and to avoid infringing
intellectual property rights of third parties; unforeseen operating risks;
the company's ability to secure collaborative agreements with third parties
for various research, development, manufacturing, marketing and other
functions; competition; risks associated with the dependence on manufacturers
of the company's proposed products; the availability of capital to finance
planned activities; and the extent to which the clinicians performing the
procedures are able to obtain third-party reimbursement. These risks are
qualified in their entirety by cautionary language and risk factors set forth
in the company's filings with the Securities and Exchange Commission.
Media Contact: Hilary Kaye or Joan Murray at Hilary Kaye Associates
(714) 426-0444 (PST) or [email protected].
Investor Relations Contact: Jonathan Fassberg at The Trout Group
(212) 477-9007 (EST) or [email protected].
###
